PharmaDossier
Manufacturing

When to Reassess Elemental Impurities After a Catalyst or Supplier Change

Use ICH Q3D(R2) to identify which evidence to revisit after a catalyst or supplier change, assess exposure, and decide whether controls or filing need to change.

Ran Chen
Ran Chen
14 min read · Published · Source-cited

Reopen the elemental impurity risk assessment and its controls when a catalyst or supplier change could alter what reaches the finished drug product. A different metallic catalyst at an active pharmaceutical ingredient (API) manufacturer and a new mineral excipient supplier are two examples. Identify the affected sources, update the total daily exposure for each element in scope, and check whether the existing controls still apply. The 30% control threshold informs the control decision. For an approved product, review the change against the marketing authorization and applicable filing rules as well. ICH Q3D(R2), sections 5 and 10 and BASG elemental impurities FAQ.

What to decide when the change arrives

Start with the change description for each affected product, strength and route of administration. Compare the old and proposed material or process, where it enters manufacture, and any downstream contact or removal steps. A supplier may be able to keep the same material specification while moving production to another site or changing a reagent outside that specification. Determine whether the evidence in the current assessment covers the proposed supply.

  1. Scope the reassessment. Identify which element, source and control assumptions the change could affect. Include dependencies, such as a shared purification step or a material supplied to several strengths.

  2. Evaluate controls. Combine the revised source contribution with other contributions to the same element. Use the applicable permitted daily exposure (PDE), the control threshold and the evidence on variability to decide whether the controls are adequate.

  3. Assess filing. Compare the actual change with the approved dossier and regional reporting rules. Start that review when scoping the change so that any reporting or approval deadline can inform the proposed implementation date.

Check Q3D scope and identify what changed

This workflow is for commercial human drug products to which Q3D applies, with examples focused on oral, parenteral and inhalation products. Section 2 covers new finished drug products, including those made with existing drug substances, and describes phased application to existing products. It excludes, among others, herbal products, radiopharmaceuticals, vaccines, gene and cell therapies, tissue-engineered products, products in clinical research, and elements added to the drug product for therapeutic benefit. Section 3.2 and Appendix 5 address other routes and cutaneous or transcutaneous products, respectively. ICH Q3D(R2), sections 2 and 3.2 and Appendix 5.

Q3D asks applicants to identify potential sources, compare observed or predicted exposure with the applicable PDE, and document the assessment and its controls. Potential sources include residues from intentional use of a catalyst or reagent, impurities already present in the API, excipients or water, and contributions from manufacturing equipment or the container closure system. Under section 10, a change in any of these inputs calls for re-evaluation when it could alter the finished product’s elemental impurity content. Check affected rows first and revisit any shared assumptions that influence their totals. ICH Q3D(R2), sections 5 and 10.

A supplier change can also prompt a separate nitrosamine assessment. This workflow follows elemental residues into the finished drug product. For the parallel supplier evidence request on nitrosamine precursors, see Nitrosamine Risk Reviews: What to Request From an API Supplier.

Record five fields for each affected source

Use one row per element and contributing source, then bring the source estimates together at the product level. Carry forward earlier evidence when it still represents the material or process in use. Record the registration or control documents that define the old and proposed configuration so a reviewer can trace the decision for each approved source.

FieldWhat to recordEvidence to check
ElementElement identity, class and the reason it enters or stays in the assessment.Catalyst or reagent disclosure, material data and Q3D Table 5.1.
Source and routeMaterial or process step, manufacturing site or supplier as relevant, and the drug product’s route of administration.Current and proposed process diagrams, material specifications or a supplier declaration tied to the changed source.
ExposureEstimated contribution per maximum daily intake, how it was derived, and how variable it could be.Representative batch data, justified carryover estimates or finished-product results, plus the approved daily dose.
ControlWhere the element is controlled and why the control covers the proposed source.Relevant purge evidence, material limits, process parameters or specifications.
VersionAssessment revision, change reference and dated evidence behind the row.Supplier documents, technical review, decision approval and follow-up criteria.

Under a component-based approach, multiply the concentration of a given element in each component (micrograms per gram) by the amount of that component in the maximum daily intake (grams per day). Sum the contributions for that element, accounting for relevant contributions from equipment and packaging where they are outside those component estimates. A representative finished-product result may already incorporate some or all of these sources. Track the basis of each result to avoid counting the same contribution twice. The PDE used for comparison comes from the element and administration route. A derived concentration limit also depends on the product’s daily intake and how the exposure is allocated across sources. ICH Q3D(R2), sections 5.6 and 7.

Which elements to revisit after a catalyst change

For oral, parenteral and inhalation products, Table 5.1 screens for Class 1 elements (arsenic, cadmium, mercury and lead) and Class 2A elements (cobalt, vanadium and nickel) even in the absence of intentional addition. The table includes any listed element that is intentionally added during manufacture. Class 2B elements such as palladium and ruthenium may generally be screened out in the absence of intentional addition. For unintentionally present Class 3 elements, the table screens in lithium, antimony and copper for parenteral products, and all seven Class 3 elements for inhalation products. Oral products generally screen out unintentionally present Class 3 elements. Use Appendix 5 for the cutaneous or transcutaneous assessment, including its concentration limits for nickel and cobalt skin sensitization where applicable. ICH Q3D(R2), sections 4 and 5.3–5.4 and Appendix 5.

Suppose the approved API source uses palladium and a proposed second source uses ruthenium. The proposed route needs a ruthenium assessment because it intentionally introduces that element. Ask which step introduces it, how much is charged, where it could persist and which downstream step controls it. Prior purge data for palladium alone leave the ruthenium carryover question open. Retain the palladium assessment for the original source while that source can still supply the product, and check whether any other source contributes either metal. Record the conclusion against each sourcing configuration so the change approval can be traced to the evidence for the lots it covers.

An element without a Q3D PDE can still matter to product quality or under regional requirements. Section 4 discusses elements that may warrant consideration for other reasons, including tungsten in therapeutic proteins. Capture any such concern in the applicable quality assessment and use the Q3D tables to determine which elements have guideline PDEs. ICH Q3D(R2), section 4.

What to ask the new supplier for

Ask the supplier to identify which material, site, process and lot range the response covers. Compare the reported elements and methods against the exposure questions still open in the assessment. For example, a certificate of analysis can provide useful results for a particular lot. Establish whether its test panel covers the element in question, whether the reporting limit is low enough for the assessment, and whether the lots represent the site or mineral source you plan to qualify.

Change or evidence gapUseful evidenceQuestion it answers
Catalyst or inorganic reagentElement identity, step of addition, quantity charged or justified range, and later steps that can remove it.Which elements could carry through to the API, and what supports the estimate?
Different purification or equipmentComparable process data, carryover or purge evidence, and product-contact material details where relevant.Does the old removal or equipment contribution estimate apply to the new process?
New mineral excipient sourceOrigin and processing site, relevant element results for representative lots, and the analytical reporting limits.Can the new material’s variability be bounded at the amount used in the drug product?
Packaging or component contact changeMaterial composition and, where relevant, evidence on leaching under the proposed storage and contact conditions.Could the new contact material add an exposure that prior data did not cover?
Limited access to supplier recordsA dated, change-specific summary with material and site identifiers, the supporting data scope, and agreed notification steps.Can the product team trace the conclusion and identify a later change that calls for review?

With a confidential drug master file, establish how the application holder will receive enough change-specific evidence to update its product assessment. Supplier documentation, published literature and data from comparable processes can all contribute if their applicability is justified. Record the gaps they leave, especially for a new mineral source where a single lot tells little about variability. ICH Q3D(R2), sections 5.5 and 5.6. For the notification and authorization workflow, see API supplier change control.

Use the 30% threshold to evaluate the controls

Section 5.6 sets the control threshold at 30% of the relevant PDE for the finished drug product. When adequate evidence and controls support a total from all sources that is consistently below that threshold, Q3D calls for no additional elemental impurity controls. A mean below the threshold can still leave variability unresolved. Compare the expected levels with both the control threshold and the PDE, and document which lots, suppliers and manufacturing conditions the estimate covers. The threshold guides the control strategy. Batch acceptance follows the applicable specifications and release procedures. ICH Q3D(R2), section 5.6.

Consider a new mineral excipient whose certificate covers the relevant elements for one shipment. Compare its mass at maximum daily intake and the contribution from other components for each element, then ask whether the supplier’s results represent the proposed mineral source and process. Its reporting limit also matters. If a reported nondetect could still represent a concentration that would use up the available margin, the result alone cannot establish the conclusion. More sensitive or representative data may resolve the gap. This is a way to decide what evidence to seek before ordering a broad test panel.

Where the assessment still cannot show that levels stay consistently below the threshold, establish controls to ensure exposure stays within the PDE. The right control may sit at the changed source, such as an excipient specification, or at a subsequent process step or the drug-product specification. Targeted testing can establish a component’s variability or check the effect of a process control. A finished-product test can assess combined exposure, while component data can help pinpoint the source. Select methods and sampling based on the question the results need to answer. Q3D discusses representative production or pilot lots at the time of submission in the absence of other justification, and notes that inherently variable materials such as mined excipients may need more data. ICH Q3D(R2), sections 5.6, 6 and 9 and FDA elemental impurities guidance, sections II.A and III.F.

Check post-approval reporting for the underlying change

Give Regulatory Affairs the precise change description, affected markets and approved dossier references, alongside the updated assessment. A catalyst switch or a packaging composition change can affect dossier commitments or quality attributes beyond elemental impurity exposure. A result below the Q3D control threshold gives evidence about elemental impurity controls. The underlying change and its potential effects determine the reporting analysis. ICH Q10, section 3.2.3.

Regulatory basisWhat to checkWhat the source establishes
EU example from Austria’s BASGDoes the new API manufacturer use a different metallic catalyst, or has the mineral excipient supplier changed? Which parts of the marketing authorization are affected?BASG calls for a documented re-evaluation of the assessment and controls for these examples, plus a variation where the applicable Commission guideline requires one.
US NDA major change, § 314.70(b)Could a change in drug substance synthesis or manufacture affect the impurity profile or other listed properties? Could new packaging type or composition affect the drug product’s impurity profile?These are examples listed under major changes. A change classified under paragraph (b) requires FDA approval of a supplement before distribution.
US NDA moderate change, § 314.70(c)Does the change have moderate potential for adverse effects under the rule, and what distribution timing applies to that specific category?Generally a supplement at least 30 days before distribution, with distribution upon FDA receipt for specified categories.
US NDA minor change, § 314.70(d)Does the evidence support minimal potential for adverse effects under the rule?Document the change in the next annual report.

The Austrian FAQ illustrates when the quality-system review is needed. Use the current Commission variations guideline and the specific authorization to classify the EU change. For an approved US new drug application (NDA), § 314.70(a)(2) requires assessing the effects before distributing product made with a manufacturing change. FDA’s 2018 guidance describes annual reporting for certain new controls added to implement Q3D or applicable compendial chapters when levels already meet the relevant PDEs. For a catalyst or supplier change, classify the manufacturing change itself using the applicable post-approval provisions. BASG elemental impurities FAQ, 21 CFR 314.70(a)–(d) and FDA elemental impurities guidance, section III.E.

Close the change with a versioned record

Connect the approved change record to the revised Q3D assessment before the new material enters the applicable commercial workflow. Specify the evidence and acceptance criteria that will be used for post-implementation verification. After implementation, record what was checked, whether the change achieved its objective, and whether product quality was affected. If verification turns up new variability or a different source than the one reviewed, reopen the affected entries. ICH Q10, section 3.2.3.

RecordWhat to retain
Change and scopeChange ID, old and new source or process, affected products, strengths and routes, and which sourcing configurations the decision covers.
Assessment and evidenceRevised document version, dated supplier or analytical evidence, rows reviewed and the basis for carrying forward any earlier estimate.
Control decisionAll-source exposure and variability rationale, applicable PDE and threshold, the controls adopted or retained, and any open evidence gaps.
Regulatory decisionAffected authorizations, classification and rationale by market, and any filing or approval needed before implementation or distribution.
Sign-off and verificationApprover and date, owner of the post-change check, evidence and criteria to use, and how any exception will be handled.

For the second-source catalyst example, the change record should let a reviewer find the ruthenium evidence for the new API, the remaining palladium assessment for the existing API, and the post-implementation check tied to the correct supplier and process. That link matters when both sources can supply commercial lots or another strength uses the same API at a different maximum daily intake.

Sources

Ran Chen
Contributing Editor
Ran Chen

Founder, PharmaDossier. Life-sciences operator covering market access, specialty pharma, biosimilars, and regulated healthcare growth.

Follow on LinkedIn →